Disclosures for "Clinical trial protocol: TRANSCEND 1 – an observational study of patients with moderate Parkinson’s disease")
-
Prof. Gesine has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Prof. Gesine has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NovoNordisk. The institution of Prof. Gesine has received research support from Swedish Research Council.
-
The institution of Prof. Widner has received research support from Academic Learing Fund, ALF. The institution of Prof. Widner has received research support from Horizon 2020, European Union. Prof. Widner has a non-compensated relationship as a Co-chair/Chair with Swedish Movement Disorders Society that is relevant to AAN interests or activities.
-
Dr. Bergholdt has received personal compensation for serving as an employee of Novo Nordisk A/S. Dr. Bergholdt has stock in Novo Nordisk A/S.
-
Ms. Frimer-Larsen has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Frimer-Larsen has stock in Novo Nordisk A/S.
-
Ms. Mathiasen has received personal compensation for serving as an employee of Novo Nordisk A/S. Ms. Mathiasen has stock in Novo Nordisk A/S.
-
Dr. Nielsen has received personal compensation for serving as an employee of Novo Nordisk. Dr. Nielsen has stock in Novo Nordisk.
-
Roger Barker, PhD has nothing to disclose.